E-Cigarette Full Nicotine

Phase 1Small molecule

JJohns Hopkins University

E-Cigarette Full Nicotine is one of 3 small molecule programs targeting E-cigarette Use. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

E-Cigarette UseRecruiting

E-Cigarette UsePhase 1

Recruiting

Competition

Competitive Landscape

2 competitors in E-Cigarette Use

#DrugCompanyPhaseTrials

Disalcid

JJoslin Diabetes Center

Phase 1

1 2

Chantix

PPrism Pharmaceuticals

Phase 1

1 3

E-Cigarette Full Nicotine

JJohns Hopkins University

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

Phase 1Recruiting

E-Cigarette Use

NCT06609109

Clinical

Trials by Indication[1]

E-cigarette Use1 trial

Effect of Cannabis on E-Cigarette Use Behavior

Recruiting·JJohns Hopkins University·Phase 1·NCT06609109·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for E-Cigarette Full Nicotine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — E-Cigarette Full Nicotine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for E-Cigarette Full Nicotine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johns Hopkins University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: JJohns Hopkins University

E-Cigarette Full Nicotine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2029

Trials by Indication[1]

E-cigarette Use1 trial

References

Drug Info

Quick Facts

Related News